Package 'CATS'

August 5, 2013

Type Package	
Title Joint power analysis for non-symetric two-stage case-control designs for SNP data	
Version 1.01	
Date 2013-08-04	
Author Anders Albrechtsen	
Maintainer Anders Albrechtsen <albred="maintainer"></albred="maintainer">	
Description Joint power analysis for two-stage designs for SNP data. Generalized so that the ratios b tween the cases and controls, the allele frequencies and the relative risk can vary between stage	
Reference Skol AD, Scott LJ, Abecasis GR, Boehnke M: Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 38: 209-213, 2006	
License GPL	
R topics documented:	
CATS-package cats print.CATS summary.CATS	1 2 4
CATS-package Power calculation for a joint analysis of a two-stage case control design for SNP data	
Description	_

Power calculation for a joint analysis of a two-stage case control design for SNP data.

Details

2 cats

Package: CATS
Type: Package
Version: 1.0
Date: 2006-10-16

License: GPL

The function cats calculates the power

Author(s)

Anders Albrechtsen

Maintainer: Anders Albrechtsen <albrecht@binf.ku.dk>

References

Skol AD, Scott LJ, Abecasis GR, Boehnke M: Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 38: 209-213, 2006.

See Also

http://www.sph.umich.edu/csg/abecasis/CaTS/

Examples

```
#calculate the power under a multiplicative model using a two stage design and #assuming a relative risk of 1.5 cats (freq=0.2, ncases=500, ncases2=500, ncontrols=1000, ncontrols2=1000, risk=1.5, multiplicative=1)
```

cats

Power calculation for a joint analysis of a two-stage case control design for SNP data

Description

Power calculation for a joint analysis of a two-stage case control design for SNP data.

Usage

```
cats(freq = 0.5, freq2 = -1, ncases = 500, ncontrols = 500, ncases2 = 500, ncontrols2 = 500, risk = 1.5, risk2 = -1, pisamples = -1, prevalence = 0.1, prevalence2 = -1, additive = 0, recessive = 0, dominant = 0, multiplicative = 1, alpha = 1e-07, pimarkers = 0.00316)
```

cats 3

Arguments

numeric. The minor allele frequency (MAF) in the first stage freq numeric. The MAF in the second stage, Optional, if -1 the same value as for the freq2 first stage is given ncases integer. The number of cases in the first stage integer. The number of controls in the first stage ncontrols ncases2 integer. The number of cases in the second stage integer. The number of controls in the second stage ncontrols2 risk numeric. The relative risk in the first stage risk2 numeric. The relative risk in the second stage, Optional, if -1 the same value as for the first stage is given numeric. The weights used for the joint statistic. Optional. see details pisamples prevalence numeric. The prevalence of the disease in the population for the first stage numeric. The prevalence of the disease in the population for the second stag, prevalence2 Optional, if -1 the same value as for the first stage is given additive boolean, if 1 an additive model is assumed recessive boolean, if 1 a recessive model is assumed boolean, if 1 a dominant model is assumed dominant multiplicative

boolean. if 1 a multiplicative model is assumed

alpha numeric. The significance threshold. Often the a threshold of 0.05 divided by

the number of markers is chosen

pimarkers numeric. The fraction of markers genotyped in the second stage

Details

These power analysis are based on Skol et al. 2006, But are generized so that the ratio between cases and controls may vary between stages. Also the allele frequencies, disease prevalence and relative risk are also allowed to vary. The joint statistic \$z_joint=z_1\sqrt\pi+z_2\sqrt1-\pi\$ where \$z_1\$ is the z-score for the first stage and the weight \$\pi\$ is calculated as \$\pi=1/\var(\hatp'_1-\hatp_1)*(1/\var(\hatp'_1-\hatp_1)+1/\var(\hatp'_2-\hatp_2))^-1\$, where \$\hatp'_1\$ is the estimate of the allele frequency of the cases in the first stage. This is consistent with Skol et al 2006 when the ratios of cases and controls are the same in both stages. When this is not the case the weight \$\pi\$ may vary slightly with different allele frequencies and different relative risks. For power calculations I would recommend calculating the weight at a likely scenario where there is about 80-90% power and fixing the weights at other scenarios (and the testing of the real data) to this weight. This can be done by assigning pisample to a value. In practice this will hardly affect the power.

Value

P.one.study The power if only one study was performed, NB! This is only a valid estimate if the relative risk and allele frequency is the same for both stages

4 cats

```
P.first.stage
                 The power for a marker to proceed the the second stage
P.rep.study
                 The power of the study if based on replication and not a joint analysis
                 The power of the joint analysis tp detect at least one susceptibility SNP assuming
P. joint.min
                  that five susceptibility SNPs exits
                 The power of the joint analysis
P. joint
pi
                 The weight used to calculate the joint statistic
                 Recommended thresholds for a one-stage study
T.one.study
T.first.stage
                  Recommended thresholds for the first stage in two-stage study
T.second.stage.rep
                 Recommended thresholds for the second stage in replication analysis
T.second.stage.joint
                 Recommended thresholds for the second stage in a joint analysis
E.Disease.freq.cases1
                 The expected disease allele frequency in stage 1 for cases
E.Disease.freq.controls1
                 The expected disease allele frequency in stage 1 for controls
E.Disease.freq.cases2
                 The expected disease allele frequency in stage 2 for cases
```

Author(s)

Anders Albrechtsen

E.Disease.freq.controls2

References

Skol AD, Scott LJ, Abecasis GR, Boehnke M: Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 38: 209-213, 2006.

The expected disease allele frequency in stage 2 for controls

See Also

http://www.sph.umich.edu/csg/abecasis/CaTS/

Examples

```
#calculate the power under a multiplicative model using a two stage design
#and assuming a relative risk of 1.5
cats(freq=0.2,ncases=500,ncases2=500,ncontrols=1000,ncontrols2=1000,
risk=1.5,multiplicative=1)

power.J<-c()
power.R<-c()
power.O<-c()
RR<-23:32/20
for(tal in 1:length(RR)){</pre>
```

print.CATS 5

```
temp<-cats(risk=RR[tal])
power.J[tal]<-temp$P.joint
power.R[tal]<-temp$P.rep.study
power.O[tal]<-temp$P.one.study
}
plot(RR,power.J,type="b",lwd=2,ylab="Power")
lines(RR,power.R,lwd=2,col=2,type="b")
lines(RR,power.O,lwd=2,col=3,type="b")
legend(1.4,0.4,c("joint analysis","replication design","one stage design"),col=1:3,lwd=3,bty="n")</pre>
```

print.CATS

prints the calculated power

Description

prints the calculated power

Usage

```
print.CATS(x, ...)
```

Arguments

x a CATS object

Dynamic parameter for the values of additional parameters for the summary method

See Also

cats

summary.CATS

summary of a CATS object

Description

```
summary of a CATS object
```

Usage

```
summary.CATS(object, ...)
```

6 summary.CATS

Arguments

object a CATS object

... Dynamic parameter for the values of additional parameters for the print method

See Also

cats

Examples

x<-cats()
summary(x)</pre>